Skip to main content
Table of Contents
Print

Do Randomised Trials Support Cannabis For MDD? 

Author: Dr. Clarissa Morton, PharmD

Recent randomised trials of cannabis for MDD have produced mixed findings. While some participants report improvements in mood, sleep, and anxiety, the overall RCT evidence remains limited and inconclusive. Researchers emphasise that larger studies are needed before cannabis can be considered a reliable treatment for major depressive disorder. 

Some trial data suggests CBD may improve emotional regulation and reduce symptoms of low mood, without the psychoactive effects of THC. However, results vary across individuals, and certain trials show little to no measurable benefit, highlighting the complexity of depression  as a condition. 

How It May Help 

Findings from randomised trials of cannabis for MDD highlight several areas where cannabinoids might offer support. While evidence is still early, these aspects are frequently explored in clinical discussions. 

RCT Evidence 

Current RCT evidence suggests modest improvements in mood and sleep among some patients with depression. However, the studies are often small and short in duration, limiting the strength of the conclusions. 

Major Depressive Disorder 

In cases of major depressive disorder, some patients in trials reported reduced rumination and better daily functioning. CBD appears more promising than THC, as it does not carry the same risks of intoxication or worsening anxiety. 

Trial Data 

Available trial data indicates that outcomes vary widely between individuals. While some experience noticeable relief, others report no significant changes, which underlines the need for more standardised research. 

In summary, randomised trials of cannabis for MDD suggest potential benefits but remain too limited to change clinical practice. The research is still in its early stages, and stronger evidence will be required to guide treatment decisions. 

For patients interested in how trial findings may relate to their own experience with major depressive disorder, providers like LeafEase can help with tailored consultations. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Depression. 

Dr. Clarissa Morton, PharmD
Author

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Categories